Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 5/20 | 0.62 |
| ▸ | AKT2 | P31751 | 9/20 | 0.60 |
| ▸ | GSK3B | P49841 | 6/20 | 0.60 |
| ▸ | KIT | P10721 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 3/20 | 0.54 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
| ▸ | TYK2 | P29597 | 1/20 | 0.53 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28379761 | 0.93 | JAK3 (0.61) | HTR2CJAK3AKT2GSK3BKIT | |
| SCHEMBL323332 | 0.84 | HTR2C (0.69) | HTR2CJAK3AKT2GSK3BKIT | |
| SCHEMBL2251760 | 0.81 | HTR2C (1.00) | HTR2CJAK3AKT2GSK3BKIT | |
| SCHEMBL15064231 | 0.80 | JAK3 (0.64) | HTR2CJAK3AKT2GSK3BKIT | |
| SCHEMBL7858238 | 0.80 | HTR2C (0.67) | HTR2CJAK3AKT2GSK3BKIT | |
| SCHEMBL2019605 | 0.80 | JAK3 (0.70) | HTR2CJAK3AKT2GSK3BKIT | |
| Hydrochloric Acid SCHEMBL30012643 | 0.79 | HTR2C (0.97) | HTR2CJAK3AKT2GSK3BKIT | |
| Hydrochloric Acid SCHEMBL29036000 | 0.79 | HTR2C (0.97) | HTR2CJAK3AKT2GSK3BKIT | |
| Hydrochloric Acid SCHEMBL2794687 | 0.79 | HTR2C (0.97) | HTR2CJAK3AKT2GSK3BKIT | |
| Piperazine SCHEMBL7852092 | 0.79 | HTR2C (0.97) | HTR2CJAK3AKT2GSK3BKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | claimed |
| US-12060352-B2 | Substituted pyrrolo[2,3-d]pyrimidines having ectonucleotide pyrophosphatase-phosphodiesterase inhibitory activity | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-08-13 | — | — | US | disclosed |
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | disclosed |
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411420-A1 | PYRROLOPYRIMIDINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE INHIBITORY ACTIVITY AND USE THEREOF | ENPP1, ENPP3, PPA1 | HTR2C 4672/4885JAK3 4097/4885AKT2 1623/4885 |
| US-12060352-B2 | Substituted pyrrolo[2,3-d]pyrimidines having ectonucleotide pyrophosphatase-phosphodiesterase inhibitory activity | ENPP1, CGAS, STING1 | HTR2C 3986/4885JAK3 2505/4885AKT2 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.